Multiple studies demonstrate that depressed patients who learned SKY experienced a 68-73% remission rate within one month. Substantial relief was experienced in three weeks. By one month, individuals were considered to be in remission. At three months, the individuals remained asymptomatic and stable, which demonstrates results persisted and cannot be considered a placebo effect.
SKY produced highly beneficial biological effects on brain and hormone function. The P300 ERP EEG brainwave pattern and NREM brainwave pattern, which measure electrical brainwave activity and are abnormal in many depressed people, returned to the normal range by ninety days. Levels of plasma cortisol (the stress hormone) decreased significantly after three weeks.
In a comparison study, SKY was statistically as effective as the conventional anti-depressant medication. Yet, in contrast to the usual treatments for depression, SKY is natural and free of unwanted side effects. It is self-administered and self-empowering. It can greatly reduce doctor and hospital caseloads, thus making SKY cost effective and staff effective as well.
Dr. Janakiramaiah, M.D., Ph.D., D.P.H., medical researcher, and Chair of Psychiatry at the National Institute of Mental Health and Neurosciences (N.I.M.H.A.N.S.) of India has conducted several of these studies. He concluded that Sudarshan Kriya has “remarkable therapeutic effects” and “is clinically feasible and effective. It has the potential to become a first-line treatment of dysthymic [chronic, mild depression] patients and possibly in mild and moderate forms of major depressive disorder.